Table 1.
Clinical trials using stem cell therapies
| Clinical trial name | Clinical trial identifier | Purpose | Status | Sponsor | Estimated study completion date |
|---|---|---|---|---|---|
| Pilot Feasibility Study of Combined Kidney and Hematopoietic Stem Cell Transplantation to Cure End-stage Renal Disease | NCT02176434 | This pilot study of combined kidney and hematopoietic stem cell transplantation attempts to establish a protocol to induce immunological tolerance as a new strategy to prevent renal graft rejection. If successful, this strategy would restore renal function, while avoiding the risks associated with long-term standard anti-rejection therapy, and would represent the first option to cure end-stage renal disease. | Recruiting | University of Zurich | August 2018 |
| Mesenchymal Stem Cells Transplantation in Patients With Chronic Renal Failure Due to Polycystic Kidney Disease | NCT02166489 | This study was designed to provide confirmation of safety of mesenchymal stem cells (MSCs) therapy in chronic renal failure due to autosomal dominant polycystic kidney disease (ADPKD). | Completed | Royan Institute, Tehran | January 2016 |
| Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients | NCT00183248 | This study will evaluate treatment of kidney transplant recipients with alemtuzumab and other immune system suppressing medications with or without infusions of bone marrow stem cells from the kidney donor. The purpose of this study is to find out which strategy is more effective in preventing organ rejection and maintaining patient health. | Completed | University of Miami | November 2009 |
| Safety and Efficacy of Autologous Bone Marrow Stem Cells for Treating Chronic Renal Failure | NCT01152411 | To evaluate the safety and efficacy (to know / observe for Proof of concept in five Indian patients) if any, of autologous bone marrow derived stem cells injected into the Renal Artery in five (initially five patients, can be increased to ten patients after observing the initial results) patients with Chronic Renal Failure | Unknown | International Stem Cell Services Limited | Unknown |
| Induction of Donor Specific Tolerance in Recipients of Living Kidney Allografts by Donor FCRx Infusion | NCT00497926 | Use of a combination of an Enriched Hematopoetic Stem Cell Infusion and kidney transplantation from the same donor to try to avoid the need for long-term anti-rejection drug therapy. The desired result of this study is to allow the body to develop “tolerance” to the transplanted kidney. | Recruiting | University of Louisville | March 2030 |
| Effect of BM-MSCs in DCD Kidney Transplantation | NCT02561767 | To determine the efficacy and safety of allogeneic bone marrow-derived mesenchymal stem cells in kidney transplantation from Chinese donation after citizen’s death (DCD). | Not yet Opened for Recruitment | Sun Yat-Sen University | October 2017 |
| Induction of Donor Specific Tolerance in Recipients of Live Donor Kidney Allografts by Donor Stem Cell Infusion | NCT00498160 | Induction of Donor Specific Tolerance in Recipients of Kidney Allografts by Donor Bone Marrow Cell Infusion (Deceased Donors) and Induction of Donor Specific Tolerance in Recipients of Live Donor Kidney Allografts by Donor Stem Cell Infusion | Current | University of Louisville | December 2024 |
| Mesenchymal Stem Cells After Renal or Liver Transplantation | NCT01429038 | To evaluate the safety and tolerability of MSC administration after liver or kidney transplantation. | Recruiting | University Hospital of Liege | February 2017 |
| Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (CKD) (RMCL-CL001) | NCT02525263 | A Phase II, Open-Label Safety and Efficacy Study of an Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (RMTX-CL001). NKA is made from expanded autologous selected renal cells (SRC) obtained from the patient’s kidney biopsy. All enrolled subjects will be treated with up to two injections of NKA at least 6 months apart. | Not yet Opened for Recruitment | RegenMed (Cayman) Ltd. | January 2018 |
| Induction Therapy With Autologous Mesenchymal Stem Cells for Kidney Allografts | NCT00658073 | To evaluate autologous MSCs as an alternative for antibody induction therapy in renal transplantation | Completed | Fuzhou General Hospital | October 2010 |
| Mesenchymal Stem Cell Transplantation in the Treatment of Chronic Allograft Nephropathy | NCT00659620 | The purpose of this study is to find out MSC is more effective in preventing organ rejection and maintaining kidney function. | Completed | Fuzhou General Hospital | May 2010 |
| Tolerance Induction in Living Donor Kidney Transplantation With Hematopoietic Stem Cell Transplantation | NCT02199301 | To evaluate the Tolerance induction in KT recipients with donor hematopoietic stem cell transplantation (HSCT). | Recruiting | Samsung Medical Center | December 2017 |
| MSC for Occlusive Disease of the Kidney | NCT01840540 | To determine the safety and toxicity of intra-arterial infused autologous adipose derived mesenchymal stromal (stem) cells in patients with vascular occlusive disease of the kidney. | Opened | Mayo Clinic | April 2017 |
| Autologous Bone Marrow Derived Mesenchymal Stromal Cells (BM-MSCs) in Patients With Chronic Kidney Disease (CKD) | NCT02195323 | To provide confirmation of safety of mesenchymal stem cells (MSCs) therapy in chronic kidney disease (CKD). | Completed | Royan Institute | January 2016 |
| Kidney and Blood Stem Cell Transplantation That Eliminates Requirement for Immunosuppressive Drugs | NCT00319657 | To determine if blood stem cells injected after kidney transplantation will change the immune system such that immunosuppressive drugs can be completely withdrawn. Patients must have a healthy, completely human leukocyte antigen (HLA)-matched brother or sister as the organ and stem cell donor. | Recruiting | Stanford University | July 2016 |
| Mesenchymal Stem Cells In Cisplatin-Induced Acute Renal Failure In Patients With Solid Organ Cancers (CIS/MSC08) | NCT01275612 | To test the feasibility and safety of systemic infusion of donor ex-vivo expanded Mesenchymal Stem Cells to repair the kidney and improve function in patients with solid organ cancers who develop acute renal failure after chemotherapy with cisplatin. | Recruiting | Mario Negri Institute for Pharmacological Research | March 2017 |
| Stem Cell Therapy for Patients With Focal Segmental Glomerulosclerosis (STEFOG) | NCT02693366 | To analyze the safety, renal function, metabolic disorders and quality of life data in patients with focal segmental glomerulosclerosis treated with endovascular infusion of bone marrow derived mononuclear cells. | Recruiting | Universidade Federal do Rio de Janeiro | June 2017 |
| Effect of BM-MSCs on Early Graft Function Recovery After DCD Kidney Transplant. | NCT02563366 | This study is designed to investigate whether allogeneic bone marrow-derived mesenchymal stem cells (BM-MSCs) can promote function recovery in patients with poor early graft function after kidney transplantation from Chinese Donation after Citizen Death (DCD). | Not yet Opened for Recruitment | Sun Yat-Sen University | December 2017 |
| Mesenchymal Stem Cells Under Basiliximab/Low Dose RATG to Induce Renal Transplant Tolerance | NCT00752479 | To define the safety and biological/mechanistic effect of the systemic intravenous infusion of syngeneic ex-vivo expanded MSCs in living-related kidney transplant recipients (one or two HLA haplotype mismatches) under basiliximab/low-dose RATG induction therapy and maintenance immunosuppressive drugs with the ultimate objective to test the feasibility of safely achieving graft tolerance in a subsequent efficacy pilot study. | Terminated | Mario Negri Institute for Pharmacological Research | December 2013 |
| Safety and Efficacy of BMMNC in Patients With Chronic Renal Failure | NCT01876017 | Single center trial to check the safety and efficacy of Autologous Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs) for the patient with CRF | Recruiting | Chaitanya Hospital, Pune | December 2016 |
| Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered in Patients With Renal Failure | NCT01453816 | An Open-label, Non-Randomised, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into the Renal Artery and Intravenously in Patients With Renal Failure | Unknown | Ageless Regenerative Institute | June 2015 |
| Hypoxia and Inflammatory Injury in Human Renovascular Hypertension | NCT02266394 | To determine if the MSC infusion prior to percutaneous transluminal renal angioplasty with stenting (PTRA) further enhances changes in single kidney blood flow and restoration of kidney function, as well as to assess the relationship between MSC dose and measures of kidney function. | Recruiting | Mayo Clinic | March 2019 |
| To Elucidate the Effect of Mesenchymal Stem Cells on the T Cell Repertoire of the Kidney Transplant Patients | NCT02409940 | Aim To investigate effect of MSCs on immune cell repertoire in a donor specific mediated response. | Recruiting | Postgraduate Institute of Medical Education and Research | December 2016 |
| Mesenchymal Stem Cell Transplantation in the Treatment of Chronic Allograft Nephropathy | NCT00659620 | Mesenchymal Stem Cell (MSC) has been shown to have immunosuppressive and repairing properties. the investigators will infuse expanded MSC into patients who develop Chronic Allograft Nephropathy. The purpose of this study is to find out MSC is more effective in preventing organ rejection and maintaining kidney function | Unknown | Fuzhou General Hospital | May 2010 |
Stem Cells and Kidney Disease – Clinical Trials; Source: www.ClinicalTrials.gov